TY - JOUR AU - Ahmed, Nehad J. PY - 2022/09/15 Y2 - 2024/03/29 TI - Drug-Induced Insomnia: Descriptive analysis of FDA Adverse Event Reporting System JF - Asian Journal of Pharmaceutics (AJP) JA - AJP VL - 16 IS - 3 SE - ORIGINAL ARTICLES DO - 10.22377/ajp.v16i3.4489 UR - http://asiapharmaceutics.info/index.php/ajp/article/view/4489 SP - AB - <p>Aim: Insomnia is one the most common problems encountered by the family physician and can occur due to<br>several causes such as using some drugs. The present study aimed to describe the reports that were submitted to<br>FDA Adverse Event Reporting System (FAERS) about drug-induced insomnia. Materials and Methods: The<br>FAERS was used to conduct this retrospective study that comprised a descriptive analysis of all reported adverse<br>events of drug-induced insomnia in the past 5 years. Results: During the study period from the beginning of<br>2017 to the end of 2021, there were 86918 reports about drug-induced insomnia submitted to FAERS. The most<br>frequently reported drugs were levothyroxine sodium (3.85%), duloxetine hydrochloride (3.24%), adalimumab<br>(3.08%), pregabalin (2.71%), etanercept (2.17%), and niraparib (2.04%). Conclusion: It is important to increase<br>the awareness of healthcare workers about the medications that could cause insomnia. Moreover, health-care<br>providers should educate the patients about the drugs that could induce insomnia, how they can manage insomnia,<br>and how they can report these adverse effects.</p> ER -